Composition and methods of treating B cell disorders
AssigneeDana-Farber Cancer Institute, Inc.
InventorWayne A. Marasco
Life of this patent
Estimating the term…
Abstract
The present invention comprises methods of using a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69 to treat B-cell disorders.
Claims12
A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising contacting the B-cell with a chimeric antigen receptor comprising an huG6 antibody.
A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising administering to a subject in need thereof a chimeric antigen receptor comprising an huG6 antibody.
A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising contacting the B-cell with a chimeric antigen receptor comprising an huG6 antibody, wherein said chimeric antigen receptor comprising an huG6 antibody is contacted with the B-cell prior to, concurrently with, or subsequent to contacting the B-cell with a chemotherapeutic agent.
A method of selectively killing a B-cell expressing a IGHV1-69 BCR comprising administering to a subject in need thereof a chimeric antigen receptor comprising an huG6 antibody, wherein said chimeric antigen receptor comprising an huG6 antibody is administered to, concurrently with, or subsequent to the administration of a chemotherapeutic agent.
Dependencies are inferred from the claim text.